ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement. 

An independent heart team blinded to ICA results was able to deliver helpful guidance for CABG procedures for 99.1% of patients using just CCTA and FFR_CT alone. This approach is safe and feasible, researchers wrote, and the next step is to gather additional data. 

The company's new AI offering, a product of its 2023 acquisition of Caption Health, will make its debut at ACC.24 in Atlanta.

Eko Health worked closely with Mayo Clinic to develop and evaluate its latest AI offering. “Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations," one clinician said. 

Cardiologists were asked to develop a care strategy for CAD patients before and after using an FDA-approved AI tool to evaluate CT results. In two out of three cases, the AI influenced cardiologists to modify their original plan. 

HeartFlow hopes to gather real-world data from up to 10,000 patients with suspected CAD.

The newly approved AI models are designed to improve the detection of pulmonary embolisms and strokes in patients who undergo CT scans.

The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab.